Development of disulfide-stabilized Fabs for targeting of antibody-directed nanotherapeutics

References

• Harding JA, Engbers CM, Newman MS, Goldstein NI, Zalipsky S. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta. 1997;1327(2):181–10. doi:10.1016/S0005-2736(97)00056-4.
   PubMed Web of Science ®Google Scholar
• Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets. 2004;8(4):335–53. doi:10.1517/14728222.8.4.335.
   PubMed Web of Science ®Google Scholar
• Cheng WW, Allen TM. The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment. Expert Opin Drug Deliv. 2010;7(4):461–78. doi:10.1517/17425240903579963.
   PubMed Web of Science ®Google Scholar
• Cheng WW, Das D, Suresh M, Allen TM. Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. Biochim Biophys Acta. 2007;1768(1):21–29. doi:10.1016/j.bbamem.2006.09.004.
   PubMed Web of Science ®Google Scholar
• Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, et al. Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. Nat Biomed Eng. 2019;3(4):264–80. doi:10.1038/s41551-019-0385-4.
   PubMed Web of Science ®Google Scholar
• Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003;63:3154–61.
   PubMed Web of Science ®Google Scholar
• Nellis DF, Giardina SL, Janini GM, Shenoy SR, Marks JD, Tsai R, Drummond DC, Hong K, Park JW, Ouellette TF, et al. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog. 2005;21(1):221–32. doi:10.1021/bp049839z.
   PubMed Web of Science ®Google Scholar
• Quintero-Hernandez V, Juarez-Gonzalez VR, Ortiz-Leon M, Sanchez R, Possani LD, Becerril B. The change of the scFv into the Fab format improves the stability and in vivo toxin neutralization capacity of recombinant antibodies. Mol Immunol. 2007;44(6):1307–15. doi:10.1016/j.molimm.2006.05.009.
   PubMed Web of Science ®Google Scholar
• Rothlisberger D, Honegger A, Pluckthun A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol. 2005;347(4):773–89. doi:10.1016/j.jmb.2005.01.053.
   PubMed Web of Science ®Google Scholar
• Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D. Sterically Stabilized Anti-HER2 Immunoliposomes:  design and Targeting to Human Breast Cancer Cells in Vitro. Biochemistry. 1997;36(1):66–75. doi:10.1021/bi962148u.
   PubMed Web of Science ®Google Scholar
• Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, et al. Building and characterizing antibody-targeted lipidic nanotherapeutics. Methods Enzymol. 2012;502:139–66.
   PubMed Web of Science ®Google Scholar
• Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, Broadt TL, Ouellette TF, Perkins SC, Roach JM, Drummond DC, et al. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog. 2005;21(1):205–20. doi:10.1021/bp049840y.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Reiter Y, Jung SH, Lee B, Pastan I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci U S A. 1993;90(16):7538–42. doi:10.1073/pnas.90.16.7538.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Oda-Ueda N, Ueda T, Ohkuri T. A novel engineered interchain disulfide bond in the constant region enhances the thermostability of Adalimumab Fab. Biochem Biophys Res Commun. 2018;495(1):7–11. doi:10.1016/j.bbrc.2017.10.140.
   PubMed Web of Science ®Google Scholar
• Hagihara Y, Saerens D. Engineering disulfide bonds within an antibody. Biochim Biophys Acta. 2014;1844(11):2016–23. doi:10.1016/j.bbapap.2014.07.005.
   PubMed Web of Science ®Google Scholar
• Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenmeier K, Carlson M, Gadre DV, Borrok MJ, et al. Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs. 2015;7(2):377–89. doi:10.1080/19420862.2015.1007816.
   PubMed Web of Science ®Google Scholar
• Vaks L, Litvak-Greenfeld D, Dror S, Shefet-Carasso L, Matatov G, Nahary L, Shapira S, Hakim R, Alroy I, Benhar I, et al. Design principles for bispecific IgGs. Opportunities and Pitfalls of Artificial Disulfide Bonds. Antibodies (Basel). 2018;7:27. doi:10.3390/antib7030027.
   PubMedGoogle Scholar
• Pillow TH, Tien J, Parsons-Reponte KL, Bhakta S, Li H, Staben LR, Li G, Chuh J, Fourie-O’Donohue A, Darwish M, et al. Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. J Med Chem. 2014;57(19):7890–99. doi:10.1021/jm500552c.
   PubMed Web of Science ®Google Scholar
• Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315–37. doi:10.1038/nrd.2016.268.
   PubMed Web of Science ®Google Scholar
• Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, Hunter JH, Leiske CI, Miyamoto JB, Nicholas ND, et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem. 2013;24(7):1256–63. doi:10.1021/bc400217g.
   PubMed Web of Science ®Google Scholar
• Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26(8):925–32. doi:10.1038/nbt.1480.
   PubMed Web of Science ®Google Scholar
• Tumey LN, Li F, Rago B, Han X, Loganzo F, Musto S, Graziani EI, Puthenveetil S, Casavant J, Marquette K, et al. Site selection: a case study in the identification of optimal cysteine engineered antibody drug conjugates. Aaps j. 2017;19(4):1123–35. doi:10.1208/s12248-017-0083-7.
   PubMed Web of Science ®Google Scholar
• Hallam TJ, Wold E, Wahl A, Smider VV. Antibody conjugates with unnatural amino acids. Mol Pharm. 2015;12(6):1848–62. doi:10.1021/acs.molpharmaceut.5b00082.
   PubMed Web of Science ®Google Scholar
• Jacobsen FW, Stevenson R, Li C, Salimi-Moosavi H, Liu L, Wen J, Luo Q, Daris K, Buck L, Miller S, et al. Engineering an IgG scaffold lacking effector function with optimized developability. J Biol Chem. 2017;292(5):1865–75. doi:10.1074/jbc.M116.748525.
   PubMed Web of Science ®Google Scholar
• Geddie ML, Kohli N, Kirpotin DB, Razlog M, Jiao Y, Kornaga T, Rennard R, Xu L, Schoerberl B, Marks JD, et al. Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. MAbs. 2017;9(1):58–67. doi:10.1080/19420862.2016.1259047.
   PubMed Web of Science ®Google Scholar
• Kearns JD, Bukhalid R, Sevecka M, Tan G, Gerami-Moayed N, Werner SL, Kohli N, Burenkova O, Sloss CM, King AM, et al. Enhanced targeting of the EGFR network with MM-151, an oligoclonal Anti-EGFR antibody therapeutic. Mol Cancer Ther. 2015;14(7):1625–36. doi:10.1158/1535-7163.MCT-14-0772.
   PubMed Web of Science ®Google Scholar
• Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66(13):6732–40. doi:10.1158/0008-5472.CAN-05-4199.
   PubMed Web of Science ®Google Scholar
• Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci. 2008;97(11):4696–740. doi:10.1002/jps.21358.
   PubMed Web of Science ®Google Scholar
• Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev. 2015;91:3–6. doi:10.1016/j.addr.2015.01.002.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48. doi:10.1016/j.addr.2012.09.037.
   PubMed Web of Science ®Google Scholar
• Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:691–743.
   PubMed Web of Science ®Google Scholar
• Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421–46. doi:10.1038/s41573-019-0017-4.
   PubMed Web of Science ®Google Scholar
• Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta. 2001;1513(2):207–16. doi:10.1016/S0005-2736(01)00357-1.
   PubMed Web of Science ®Google Scholar
• Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 2002;62:7190–94.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu Y, Xia H, Zou J, Weaver SC, Swanson KA, Cai H, Cutler M, Cooper D, Muik A, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021;596(7871):273–75. doi:10.1038/s41586-021-03693-y.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Hayes ME, Drummond DC, Hong K, Zheng WW, Khorosheva VA, Cohen JA, Park JW, Marks JD, Benz CC, Kirpotin DB, et al. Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation. Mol Pharm. 2006;3(6):726–36. doi:10.1021/mp060040v.
   PubMedGoogle Scholar
• Parayath NN, Stephan SB, Koehne AL, Nelson PS, Stephan MT. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun. 2020;11(1):6080. doi:10.1038/s41467-020-19486-2.
   PubMed Web of Science ®Google Scholar
• Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji W, Reiman D, Bonagofski E, Wohlfahrt ME, Pillai SPS, Stephan MT, et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2017;12(8):813–20. doi:10.1038/nnano.2017.57.
   PubMed Web of Science ®Google Scholar
• Rurik JG, Tombácz I, Yadegari A, Méndez Fernández PO, Shewale SV, Li L, Kimura T, Soliman OY, Papp TE, Tam YK, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91–96. doi:10.1126/science.abm0594.
   PubMed Web of Science ®Google Scholar
• Martin F. Case study: DOXIL, the development of pegylated liposomal doxorubicin. In: Burgess D, editor. Injectable dispersed systems: formulation, processing, and performance. New York (NY): Informa Healthcare; 2007. p. 427–80.
   Google Scholar
• Morrison WR. A fast, simple and reliable method for the microdetermination of phosphorus in biological materials. Anal Biochem. 1964;7(2):218–24. doi:10.1016/0003-2697(64)90231-3.
   PubMed Web of Science ®Google Scholar